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The high prices of cancer drugs are affecting the care of patients with cancer and our health 
care system.1 In the United States, the average price of new cancer drugs increased 5- to 10-
fold over 15 years, to more than $100,000 per year in 2012. A study by Howard et al2 
documented the escalation in cancer drug prices by an average of $8500 a year over the past 
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15 years. The cost of drugs for each additional year lived (after adjusting for inflation) has 
increased from $54,000 in 1995 to $207,000 in 2013.2 This increase is causing harm to 
patients with cancer and their families. Here are the facts:
• Cancer will affect 1 in 3 individuals over their lifetime
• Recent trends in insurance coverage put a heavy financial burden on patients, 
with their out-of-pocket share increasing to 20% to 30% of the total cost3
• In 2014, all new US Food and Drug Administration (FDA)–approved cancer 
drugs were priced above $120,000 per year of use4
• The average annual household gross income in the United States is about 
$52,0005
• For a patient with cancer who needs one cancer drug that costs $120,000 per 
year, the out-of-pocket expenses could be as high as $25,000 to $30,000—more 
than half the average household income and possibly more than the median take-
home pay for a year. Patients with cancer then have to make difficult choices 
between spending their incomes (and liquidating assets) on potentially lifesaving 
therapies or foregoing treatment to provide for family necessities (food, housing, 
education). This decision is even more critical for senior citizens who are more 
frequently affected by cancers and have lower incomes and limited assets.6 
Because of costs, about 10% to 20% of patients with cancer do not take the 
prescribed treatment or compromise it.7 It is documented that the greater the out-
of-pocket cost for oral cancer therapies, the lower the compliance.8 This is a 
structural disincentive for compliance with some of the most effective and 
transformative drugs in the history of cancer treatment8
• Given the rising incidence of cancer in our aging population, high cancer drug 
prices will affect millions of Americans and their immediate families, often 
repeatedly
In 2006, the US government made a great effort to improve access to approved cancer drugs 
by requiring Medicare Part D to cover such drugs. Conversely, the 2003 Medicare 
Prescription Drug, Improvement, and Modernization Act contains legislation that forbids 
Medicare from negotiating drug prices.9 These policies have created an opportunity for drug 
companies, rendering them the sole decision makers on the price of cancer drugs.10,11 There 
is no relief in sight because drug companies keep challenging the market with even higher 
prices. This raises the question of whether current pricing of cancer drugs is based on 
reasonable expectation of return on investment or whether it is based on what prices the 
market can bear.12
The good news is that effective new cancer therapies are being developed by pharmaceutical 
and biotechnology companies at a faster rate than ever before. More than 900 new drugs are 
under development, many for rare cancers. Drug companies should be rewarded with 
reasonable profits for these efforts. The unfortunate news, also acknowledged by some of the 
pharmaceutical leadership, is that the current pricing system is unsustainable and not 
affordable for many patients.
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Patients and cancer specialists are voicing their concerns about this trend of increasing 
cancer drug prices, which ultimately harms patients with cancer and our health care system. 
Although some economic experts lament the difficulty of finding solutions, simple and 
measured incremental actions can improve the situation and allow market forces to work 
better. These actions include:
1. Creating a post-FDA drug approval review mechanism to propose a fair price for 
new treatments, based on the value to patients and heath care
2. Allowing Medicare to negotiate drug prices
3. Allowing the Patient-Centered Outcomes Research Institute, created through the 
Affordable Care Act initiatives to evaluate the benefits of new treatments, and 
similar organizations to include drug prices in their assessments of the treatment 
value
4. Allowing importation of cancer drugs across borders for personal use (eg, prices 
in Canada are about half of prices in the United States)
5. Passing legislation to prevent drug companies from delaying access to generic 
drugs (pay-for-delay)13
6. Reforming the patent system to make it more difficult to prolong product 
exclusivity unnecessarily (patent “evergreening”)
7. Encouraging organizations that represent cancer specialists and patients (eg, 
American Society of Clinical Oncology, American Society of Hematology, 
American Association for Cancer Research, American Cancer Society, National 
Comprehensive Cancer Network) to consider the overall value of drugs and 
treatments in formulating treatment guidelines
Health care in most economically advanced nations is provided to all citizens with minimal 
personal economic burdens. In the United States, health care is delivered in a profit-driven 
marketplace that commands 18% of our gross domestic product, compared with 4% to 9% in 
other industrialized nations. Despite the 2- to 3-fold higher spending per capita, the United 
States is not “number 1” in health care parameters compared with other industrialized 
nations that spend far less per capita. Rather, the United States often ranks well below 
average in several comparative studies that assess a number of measures of health care 
quality.14 Money diverted as profit does not necessarily contribute to better health outcomes, 
or even to innovation and development of novel therapies.
Drug companies, insurance companies, pharmaceutical distributors, many hospitals and 
physicians, and perhaps some patient advocacy groups can be financially conflicted when it 
comes to discussing rational drug prices. The individuals most harmed and least engaged in 
these discussions are cancer patients because they are exhausting their energy, resources, and 
time fighting for their lives. Patients should voice their concerns and take a page from the 
history of AIDS advocacy strategies that resulted, within 2 decades of the start of the AIDS 
epidemic, in the FDA approval of more than 35 AIDS drugs15 that now prevent most AIDS 
deaths and allow patients to live normal lives, with affordable AIDS drugs available to all.
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A cancer patient–based grassroots movement that advocates against the high price of cancer 
drugs can accomplish a great deal. One such movement, a petition, is already available and 
is actively collecting signees. It has been designed to be signed online on Change.org (short 
link URL: http://chn.ge/1DCWT1M) and is publicized on e-mail 
(stophighdrugcosts@gmail.com), on Facebook (https://www.facebook.com/
stophighdrugcosts), and on Twitter (@StopHighRxCosts), thus using contemporary methods 
to address a contemporary crisis. Those encouraged to sign the petition include patients, 
relatives, friends, supporters, health care professionals, and others. Should this petition or 
any other similar grassroots efforts generate in aggregate an immense number of unique 
supporters (eg, >1 million petition signees or a comparable mass action quantified in other 
terms), this quantified support can then be used by advocates, lobbyists, and others to 
advocate against the aforementioned harms generated by the high price of cancer drugs. 
With proper support of these grassroots efforts, and proper use of that support downstream, 
it should be possible to focus the attention of pharmaceutical companies on this problem and 
to encourage our elected representatives to more effectively advocate for the interests of 
their most important constituents among the stakeholders in cancer—American cancer 
patients.
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